Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Salles, Gilles  [Clear All Filters]
2015
Sarkozy C, Salles G, Falandry C. The Biology of Aging and Lymphoma: a Complex Interplay. Curr Oncol Rep. 2015;17(7):457.
Lepretre S, Touzart A, Vermeulin T, Picquenot J-M, Tanguy-Schmidt A, Salles G, Lamy T, Béné M-C, Raffoux E, Huguet F, et al. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. J Clin Oncol. 2015.
2019
Balsat M, Pillet S, Tavernier E, Cacheux V, Escuret V, Moluçon-Chabrot C, Augeul-Meunier K, Mirand A, Regagnon C, Tinquaut F, et al. Human Herpesvirus 6 Infection after Autologous Stem Cell Transplantation: A Multicenter Prospective Study in Adult Patients. J Infect. 2019.
Mounier N, Anthony S, Busson R, Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas R-O, Morschhauser F, Feugier P, et al. Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study. Cancer. 2019.
Conrad A, Boccard M, Valour F, Alcazer V, Sanchez A-TTovar, Chidiac C, Laurent F, Vanhems P, Salles G, Brengel-Pesce K, et al. VaccHemInf project: protocol for a prospective cohort study of efficacy, safety and characterisation of immune functional response to vaccinations in haematopoietic stem cell transplant recipients. BMJ Open. 2019;9(2):e026093.
2020
Sesques P, Bourcier J, Golfier C, Lebras L, Nicolas-Virelizier E, Hacini M, Perrin MClaire, Voillat L, Bachy E, Traverse-Glehen A, et al. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era. Hematol Oncol. 2020.
Conrad A, Perry M, Langlois M-E, Labussière-Wallet H, Barraco F, Ducastelle-Lepretre S, Larcher M-V, Balsat M, Boccard M, Chidiac C, et al. Efficacy and safety of revaccination against tetanus, diphtheria, Haemophilus influenzae type b and hepatitis B virus in a prospective cohort of adult recipients of allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020.
Salles G, Duell J, Barca EGonzález, Tournilhac O, Jurczak W, Liberati AMarina, Nagy Z, Obr A, Gaidano G, André M, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020.
Awasthi R, Pacaud L, Waldron E, Tam CS, Jäger U, Borchmann P, Jaglowski S, Foley SRonan, van Besien K, Wagner-Johnston ND, et al. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Adv. 2020;4(3):560-572.
2021
Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021.
2022
Hermine O, Jiang L, Walewski J, Bosly A, Thieblemont C, Szymczyk M, Pott C, Salles G, Feugier P, Hübel K, et al. High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2022:JCO2201780.
Martin P, Cohen JB, Wang M, Kumar A, Hill B, Villa D, Switchenko JM, Kahl B, Maddocks K, Grover NS, et al. Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. J Clin Oncol. 2022:JCO2102698.
Nath K, Tomas AAlarcon, Flynn J, Fein JA, Alperovich A, Anagnostou T, Batlevi CLee, Dahi PB, Fingrut WB, Giralt SA, et al. Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma: Vitamin D insufficiency and CAR-T in LBCL. Transplant Cell Ther. 2022.
2023
Boardman AP, Salles G. CAR T-cell therapy in large B cell lymphoma. Hematol Oncol. 2023;41 Suppl 1:112-118.
Ptashkin RN, Ewalt MD, Jayakumaran G, Kiecka I, Bowman AS, Yao JJ, Casanova J, Lin Y-TDavid, Petrova-Drus K, Mohanty AS, et al. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing. Nat Commun. 2023;14(1):6895.
Epstein-Peterson ZD, Drill E, Aypar U, Batlevi CLee, Caron P, Dogan A, Drullinsky P, Gerecitano J, Hamlin PA, Ho C, et al. Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation. Haematologica. 2023.
Nowakowski GS, Yoon DHyun, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, et al. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large . Ann Hematol. 2023.
Duell J, Abrisqueta P, André M, Gaidano G, Gonzales-Barca E, Jurczak W, Kalakonda N, Liberati AMarina, Maddocks KJ, Menne T, et al. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety in the phase II L-MIND study. Haematologica. 2023.
2024
Krystel-Whittemore M, Petrova-Drus K, Ptashkin RN, Ewalt MD, Yao JJ, Liu Y, Zhu M, Benhamida J, Durham B, Kumar J, et al. Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies. Haematologica. 2024.